Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)

NCT02722044 is registered in ClinicalTrials.gov with Momenta Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02722044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02722044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Lead sponsor
Momenta Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2016
Completion date
February 21, 2017
Enrollment
33 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis